MX2020010231A - Una combinacion farmaceutica triple que comprende dabrafenib, trametinib y un inhibidor de erk. - Google Patents
Una combinacion farmaceutica triple que comprende dabrafenib, trametinib y un inhibidor de erk.Info
- Publication number
- MX2020010231A MX2020010231A MX2020010231A MX2020010231A MX2020010231A MX 2020010231 A MX2020010231 A MX 2020010231A MX 2020010231 A MX2020010231 A MX 2020010231A MX 2020010231 A MX2020010231 A MX 2020010231A MX 2020010231 A MX2020010231 A MX 2020010231A
- Authority
- MX
- Mexico
- Prior art keywords
- dabrafenib
- trametinib
- pharmaceutical combination
- erk inhibitor
- triple
- Prior art date
Links
- 239000012824 ERK inhibitor Substances 0.000 title abstract 2
- 229960002465 dabrafenib Drugs 0.000 title abstract 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004066 trametinib Drugs 0.000 title abstract 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 title abstract 2
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650744P | 2018-03-30 | 2018-03-30 | |
| PCT/IB2019/052601 WO2019186488A1 (en) | 2018-03-30 | 2019-03-29 | A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010231A true MX2020010231A (es) | 2020-10-28 |
Family
ID=66397350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010231A MX2020010231A (es) | 2018-03-30 | 2019-03-29 | Una combinacion farmaceutica triple que comprende dabrafenib, trametinib y un inhibidor de erk. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210121460A1 (enExample) |
| EP (1) | EP3773586A1 (enExample) |
| JP (1) | JP2021519285A (enExample) |
| KR (1) | KR20200138303A (enExample) |
| CN (1) | CN111936141A (enExample) |
| AU (1) | AU2019246719B2 (enExample) |
| BR (1) | BR112020019577A2 (enExample) |
| CA (1) | CA3094780A1 (enExample) |
| CL (1) | CL2020002505A1 (enExample) |
| IL (1) | IL277380A (enExample) |
| MX (1) | MX2020010231A (enExample) |
| RU (1) | RU2020135055A (enExample) |
| WO (1) | WO2019186488A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230090389A1 (en) * | 2020-02-28 | 2023-03-23 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| IL295626A (en) * | 2020-02-28 | 2022-10-01 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor |
| KR20240055721A (ko) * | 2021-06-24 | 2024-04-29 | 아사나 바이오사이언시스 엘엘씨 | Erk1/2 억제제 조합 요법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DK3063143T3 (en) * | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
-
2019
- 2019-03-29 AU AU2019246719A patent/AU2019246719B2/en not_active Ceased
- 2019-03-29 MX MX2020010231A patent/MX2020010231A/es unknown
- 2019-03-29 CA CA3094780A patent/CA3094780A1/en active Pending
- 2019-03-29 WO PCT/IB2019/052601 patent/WO2019186488A1/en not_active Ceased
- 2019-03-29 BR BR112020019577-4A patent/BR112020019577A2/pt not_active Application Discontinuation
- 2019-03-29 CN CN201980021573.3A patent/CN111936141A/zh active Pending
- 2019-03-29 KR KR1020207030757A patent/KR20200138303A/ko not_active Withdrawn
- 2019-03-29 JP JP2020551481A patent/JP2021519285A/ja active Pending
- 2019-03-29 RU RU2020135055A patent/RU2020135055A/ru unknown
- 2019-03-29 EP EP19721810.0A patent/EP3773586A1/en not_active Withdrawn
- 2019-03-29 US US17/042,591 patent/US20210121460A1/en not_active Abandoned
-
2020
- 2020-09-15 IL IL277380A patent/IL277380A/en unknown
- 2020-09-28 CL CL2020002505A patent/CL2020002505A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3094780A1 (en) | 2019-10-03 |
| CN111936141A (zh) | 2020-11-13 |
| BR112020019577A2 (pt) | 2021-01-05 |
| IL277380A (en) | 2020-11-30 |
| KR20200138303A (ko) | 2020-12-09 |
| CL2020002505A1 (es) | 2021-03-05 |
| JP2021519285A (ja) | 2021-08-10 |
| EP3773586A1 (en) | 2021-02-17 |
| AU2019246719A1 (en) | 2020-10-01 |
| US20210121460A1 (en) | 2021-04-29 |
| AU2019246719B2 (en) | 2022-06-16 |
| WO2019186488A1 (en) | 2019-10-03 |
| RU2020135055A (ru) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4249000A3 (en) | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor | |
| MX2021009563A (es) | Combinacion farmaceutica que comprende tno155 y ribociclib. | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| PH12022550399A1 (en) | MTA-Cooperative PRMT5 Inhibitors | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12022550469A1 (en) | Kras g12d inhibitors | |
| MX2021009562A (es) | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| MX2021001376A (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| MX2022010944A (es) | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. | |
| EP4691567A3 (en) | Jak1 pathway inhibitor for use in the treatment of chronic lung allograft dysfunction | |
| SG10201907699YA (en) | Substituted pyrazole compounds as serine protease inhibitors | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
| PH12019501893A1 (en) | Methods for increasing blood plasma 2`-deoxyuridine (durd) and thymidylate synthase inhibition | |
| TN2017000465A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| MX2025012183A (es) | Formas cristalinas de un inhibidor de ras | |
| EP4512407A3 (en) | Oligonucleotides for modulating rtel1 expression |